CroiValve Limited

CroíValve is an early stage medical device company who are developing a transcatheter device to treat Tricuspid Regurgitation, a common heart valve disorder. Current treatment involves highly invasive, risky, open-heart surgery. CroíValve’s minimally-invasive technology employs well-established delivery techniques to repair the tricuspid valve without the need for surgery. CroíValve’s unique selling proposition is that the device is safer, more effective, less traumatic, and easier to deliver than competing technologies. We’re now raising finance to transform the standard of care for these patients and open up this €3 billion market.